Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Acquires $21,945.00 in Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel acquired 1,500 shares of the business’s stock in a transaction on Thursday, September 26th. The stock was acquired at an average cost of $14.63 per share, for a total transaction of $21,945.00. Following the transaction, the chief executive officer now directly owns 5,536,102 shares in the company, valued at $80,993,172.26. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Snehal Patel also recently made the following trade(s):

• On Monday, August 5th, Snehal Patel bought 5,500 shares of Greenwich LifeSciences stock. The shares were bought at an average cost of $13.18 per share, with a total value of $72,490.00.
• On Tuesday, July 23rd, Snehal Patel purchased 1,500 shares of Greenwich LifeSciences stock. The stock was bought at an average cost of $15.89 per share, for a total transaction of $23,835.00.

Greenwich LifeSciences Stock Up 0.8 %

Shares of NASDAQ:GLSI opened at $13.97 on Thursday. The business’s 50 day moving average is $14.36 and its 200 day moving average is $15.01. The stock has a market cap of $179.93 million, a P/E ratio of -19.40 and a beta of 1.61. Greenwich LifeSciences, Inc. has a 52-week low of $7.58 and a 52-week high of $21.44.

Greenwich LifeSciences (NASDAQ:GLSI) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.20). On average, sell-side analysts anticipate that Greenwich LifeSciences, Inc. will post -0.81 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its stake in shares of Greenwich LifeSciences by 0.6% during the first quarter. Vanguard Group Inc. now owns 223,102 shares of the company’s stock valued at $4,449,000 after purchasing an additional 1,420 shares in the last quarter. Rhumbline Advisers purchased a new stake in Greenwich LifeSciences during the second quarter worth $117,000. Finally, Bank of New York Mellon Corp bought a new stake in Greenwich LifeSciences during the 2nd quarter valued at $264,000. Hedge funds and other institutional investors own 4.16% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright upped their target price on shares of Greenwich LifeSciences from $36.00 to $38.00 and gave the stock a “buy” rating in a research note on Friday, August 23rd.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.